Roche, Genentech: Inavolisib Gets FDA Breakthrough Status To Treat Breast Cancer With Mutation

Swiss drug major Roche Holding AG (RHHBY) and its U.S. Unit Genentech announced Tuesday that the U.S. Food and Drug Administration has granted Breakthrough Therapy Designation for inavolisib to treat advanced hormone receptor-positive, HER2-negative breast cancer with a PIK3CA mutation.

Related Keywords

Switzerland , Swiss , Levi Garraway , European Medicines Agency , More Such Health News , Head Of Global Product Development , Roche Holding , Drug Administration , Breakthrough Therapy Designation , Therapy Designation , Chief Medical Officer , Global Product Development , European Medicines ,